CD19 chimeric antigen receptor-T cells as bridging therapy to allogeneic hematopoietic cell transplantation improves outcome in patients with refractory/relapsed B-cell acute lymphoblastic leukemia

Chimeric antigen receptor (CAR)-T cell therapy has been confirmed improving remission rates in refractory patients or relapsed B-cell acute lymphoblastic leukemia (R/R B-ALL). However, the added benefits of undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) following CAR-T the...

Täydet tiedot

Bibliografiset tiedot

Päätekijät:	Jie Liu, Mengyuan Xu, Xiaoqian Zhang, Zhuo Zhang, Tao Zhong, Hongjuan Yu, Yueyue Fu, Hongbin Meng, Jiawei Feng, Xindi Zou, Xueying Han, Liqing Kang, Lei Yu, Limin Li
Aineistotyyppi:	Artigo
Kieli:	Inglês
Julkaistu:	Elsevier 2024-07-01
Sarja:	Heliyon
Aiheet:	B-cell acute lymphoblastic leukemia Allogeneic hematopoietic stem cell transplantation, Chimeric antigen receptor-T Refractory Relapsed
Linkit:	http://www.sciencedirect.com/science/article/pii/S2405844024099687
Tagit:	Lisää tagi Ei tageja, Lisää ensimmäinen tagi!